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Insights into gene expression 
profiles induced by Socs3 depletion 
in keratinocytes
Archana Bajpai1, Takashi Ishii1, Kosuke Miyauchi2, Vipul Gupta  1,3, Yuka Nishio-Masaike1, 
Yuki Shimizu-Yoshida1,5, Masato Kubo2,4 & Hiroaki Kitano1,3,5,6
Specific deletion of suppressor of cytokine signaling 3 (Socs3) in keratinocytes can cause severe 
skin inflammation with infiltration of immune cells. The molecular mechanisms and key regulatory 
pathways involved in these processes remain elusive. To investigate the role of Socs3 in keratinocytes, 
we generated and analyzed global RNA-Seq profiles from Socs3 conditional knockout (cKO) mice of 
two different ages (2 and 10 weeks). Over 400 genes were significantly regulated at both time points. 
Samples from 2-week-old mice exhibited down-regulation of genes involved in keratin-related functions 
and up-regulation of genes involved in lipid metabolism. At week 10, multiple chemokine and cytokine 
genes were up-regulated. Functional annotation revealed that the genes differentially expressed 
in the 2-week-old mice play roles in keratinization, keratinocyte differentiation, and epidermal cell 
differentiation. By contrast, differentially expressed genes in the 10-week-old animals are involved in 
acute immune-related functions. A group of activator protein-1–related genes were highly up-regulated 
in Socs3 cKO mice of both ages. This observation was validated using qRT-PCR by SOCS3-depleted 
human keratinocyte–derived HaCaT cells. Our results suggest that, in addition to participating in 
immune-mediated pathways, SOCS3 also plays important roles in skin barrier homeostasis.
Skin is an essential organ that consists of two major layers, the epidermis and dermis. The epidermis, the outer-
most layer of skin tissue, consists of keratinocytes, which perform diverse biological functions. In particular, the 
epidermis controls multiple intercellular immune responses by producing cytokines that promote maintenance of 
skin barrier homeostasis1,2. Cytokines are essential intercellular mediators of immune signals regulated by SOCS 
(Suppressor of Cytokine Signaling) family proteins, which communicate extensively with various cellular and 
molecular responses via the JAK–STAT (Janus kinase–signal transducer and activator of transcription) pathway 
and dynamically regulate tissue hemostasis3–5. Although these systems are robust, perturbation of any of their 
components can lead to a variety of diseases, including allergy, autoimmune skin diseases, inflammation, and 
cancers5–11.
Recently, several groups extensively investigated the role of SOCS family proteins in skin homeostasis and 
inflammation, and sought to determine how dysregulation of skin hemostasis leads to altered cutaneous immune 
responses during inflammatory pathogenesis in the skin2,12,13. The role of SOCS3 in immune regulation is well 
established14–16. Moreover, a recent study using transgenic mice showed that dysregulation of Socs3, but not Socs1, 
in keratinocytes results in hyper-active immune responses and hyperplasia in the epidermis, eventually leading to 
a psoriasis-like phenotype13. This observation implies that Socs3 governs cellular processes beyond the immune 
response; however, the underlying molecular mechanisms and key regulatory pathways underlying the sequential 
breaching of the skin barrier and induction of inflammation in the absence of Socs3 remain poorly understood.
To investigate the role of Socs3 in epidermal homeostasis, we used RNA-Seq to systematically analyze differen-
tial gene expression profiles of cells from 2 and 10 week-old Socs3 cKO mice. We identified the most significantly 
altered genes, as well as the highly enriched biological pathways and networks crucial for epidermal hemostasis. 
In addition, we validated our RNA-Seq analysis results by qRT-PCR in cultured human keratinocytes. Our results 
1RIKEN-IMS, Laboratory for Disease Systems Modeling, Yokohama, Japan. 2RIKEN-IMS, Laboratory for Cytokine 
Regulation, Yokohama, Japan. 3The Systems Biology Institute, Tokyo, Japan. 4Division of Molecular Pathology, 
Research Institute for Biomedical Science, Tokyo University of Science, Tokyo, Japan. 5Sony Computer Science 
Laboratories, Inc, Tokyo, Japan. 6Okinawa Institute of Science and Technology, Okinawa, Japan. Correspondence and 
requests for materials should be addressed to A.B. (email: archana.bajpai@riken.jp) or H.K. (email: hiroaki.kitano@
riken.jp)
Received: 15 February 2017
Accepted: 8 November 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIfIC RepoRTS | 7: 15830  | DOI:10.1038/s41598-017-16155-1
suggest that Socs3 not only controls immune homeostasis, but also promotes maintenance of epidermal homeo-
stasis. Our findings provide new molecular insights into how perturbed epidermal homeostasis contributes to the 
development of skin diseases.
Results
Altered gene expression profiles in Socs3 cKO keratinocytes at 2 and 10 weeks. To investigate 
the global molecular perturbations associated with deletion of Socs3 in keratinocytes, we compared gene expres-
sion between wild-type (C57BL/6 mice) and Socs3 conditional knockout (Socs3 cKO) mice at two different ages, 2 
and 10 weeks. RNA-Seq reads were first aligned to the mouse genome (mm9) using TopHat217. Raw gene counts 
were then normalized and expressed as frequency per kilobase per million mapped reads (FPKM) for 21110 genes 
annotated in the reference genome database18,19. Next, annotated genes were analyzed using the EdgeR package20 
in the R statistical environment, and statistically significant differentially expressed genes (DEGs) were identified 
based on their calculated log2 fold changes [|log2(FC)| ≥ 1] and false discovery rates (FDR < 0.01) at both time 
points (Fig. 1A, Supplementary Table S1). A total of 2394 and 1518 genes were differentially expressed at 2 and 10 
weeks, respectively (Fig. 1B). Approximately 50% of DEGs were either up-regulated or down-regulated at both 2 
and 10 weeks (Fig. 1B), with 448 common DEGs (Fig. 1A). To highlight the major differences in the expression 
profiles of 2- and 10-week-old mice, we applied a stringent fold-change threshold [|log2(FC)| ≤ 4, FDR < 0.01] 
and generated a heat map of the 165 DEGs with the greatest perturbation in expression levels in either of the two 
samples (Fig. 1C). Clear distinctive patches of DEGs were found to be up- or down-regulated (Fig. 1C).
To further identify and characterize the molecular basis of DEGs in Socs3 cKO samples, we performed Gene 
Ontology (GO) pathway enrichment analysis21. In the 2 week samples, the results revealed significant enrichment 
of skin-related GO terms, including keratinization (GO:0031424), keratinocyte differentiation (GO:0030216), 
cornification (GO:0070268), and epidermal cell differentiation (GO:0009913). By contrast, GO terms related to 
response to external stimulus (GO:0009605), cellular response to chemical stimulus (GO:0070887), regulation of 
apoptotic process (GO:0042981), and regulation of cell death (GO:0010941) were highly enriched in the 10 week 
samples.
Figure 1. Gene expression profiles in Socs3 cKO. (A) Venn diagrams indicating the numbers of differentially 
expressed genes (DEGs) between Socs3 cKO and the wild type at two ages, 2 and 10 weeks [p < 0.05, 
FDR < 0.01, |log2(fold change)| ≥ −1]. (B) Bar chart representing the total numbers of genes that were up-
regulated (red) or down-regulated (green) in Socs3 cKO at both time points. (C) Heat map representing 
the expression profiles of the top 165 up-regulated (red) [FDR ≤ 0.01 and |log2(fold change)| ≥ 4] and 
down-regulated (green) (FDR  ≤ 0.01 and |log2(fold change)| ≥ 4) genes in 2- and 10-week-old Socs3 cKO in 
comparison with the wild type. Wild type: 2 weeks, n = 6; 10 weeks, n = 4. Socs3 cKO: 2 weeks, n = 4; 10 weeks, 
n = 4.
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Dynamics of altered gene expression profiles in Socs3 cKO keratinocytes at 2 and 10 weeks. To 
further elucidate the role of Socs3 in keratinocytes at early stages of development, we selected the top 20 most sig-
nificant DEGs with the largest decreases and increases in transcript levels in 2- and 10-week-old Socs3 cKO mice. 
As shown in Fig. 2 (left), all keratin-associated genes crucial for formation of the epidermis, keratinization, epi-
dermal growth and barrier function, and formation of the cornified envelope were significantly down-regulated 
in 2-week-old Socs3 cKO mice. S100a8 and S100a9, which encodes a calcium-binding protein also known as 
calprotectin, an early biomarker of psoriasis, were among the most up-regulated genes22–25. Also up-regulated 
were the genes encoding small proline-rich protein 2i (Sprr2i), serine protease (SP) inhibitor (Serpinb7), and beta 
defensin (Defb14), which play major roles in desquamation and control of skin barrier homeostasis26–28.
To understand the dynamics of gene expression in Socs3 cKO mice, we then analyzed the data from the 
10-week-old mice. In contrast with the younger mice, the most up-regulated genes in the older mice were 
enriched in functions related to acute immune responses, including multiple chemokines (Cxcl1, Cxl2), an inter-
leukin cytokine (Il-6), Fos, Fosl1, and Fosb (Fig. 2, right). Clec3a, which encodes a C-type lectin family member 
that inhibits activation of CD4 + T cells and plays an important role in immune regulation, was up-regulated by 
16-fold. The most down-regulated genes included Dub1(deubiquinating enzyme 1), Nkx2-1(homeodomain tran-
scription factor; TF), Zfp488, and Zfp457 (zinc finger proteins 488 457) (Fig. 2, right). Interestingly, Defb14, Il-6, 
and genes related to S100 are overexpressed in the skin disease initiated by loss of Socs3 in keratinocytes, leading 
Figure 2. Differentially expressed genes (DEGs) in Socs3 cKO samples. Top 20 up-regulated (red) and down-
regulated (green) DEGs at 2 and 10 weeks in Socs3 cKO [FDR ≤ 0.01 and |log2(fold change)| ≥ 2].
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to a severe skin condition in older mice13. It is likely that these genes represent ‘first responders’ in which dramatic 
expression changes contribute to the onset of skin disease.
Analysis of enriched function and disease-associated pathways in 2- and 10-week-old mice. 
Next, we used Ingenuity Pathway Analysis (IPA) to identify enriched biological processes and molecular func-
tions altered by loss of Socs3. Comparison of wild-type and Socs3 cKO DEGs at 2 weeks revealed that the most 
enriched pathways in the knockout animals were ‘LXR/RXR (liver X receptor/retinoid X receptor) signaling’ [−
log(p-value) = 5.81] and ‘PPAR (peroxisome proliferator–activated receptors) signaling’ [−log(p-value) = 5.25] 
(Fig. 3A). The LXR/RXR and PPAR pathways regulate multiple genes involved in lipid biosynthesis and metab-
olism. In patients with inflammatory skin disorders or epidermal psoriasis, PPAR expression is significantly 
altered29. Dysregulation of lipid metabolism and oxidative pathways are among the early signatures of skin 
inflammation. In epidermal psoriasis, levels of total lipids, low-density lipoproteins (LDL), and phospholipids 
are significantly elevated, concomitant with activation of inflammatory responses mediated by the innate and 
adaptive immune systems30–35. Consistent with this, ‘acute phase response signaling’ [−log(p-value) = 4.32], ‘IL-6 
(interleukin 6) signaling’ [−log(p-value) = 4.07], and ‘p38 MAPK signaling’ [−log(p-value) = 3.64] were also 
highly enriched at 2 weeks in Socs3 cKO mice (Fig. 3A, Supplementary Table S2).
At 10 weeks, the top 10 enriched pathways included ‘ERK5 signaling’ [−log(p-value) = 6.66], ‘Gα12/13 signa-
ling’ [−log(p-value) = 3.81], ‘RhoGDI Signaling’ [−log(p-value) = 3.41], ‘TREM-1 signaling’ (triggering receptor 
expressed on myeloid cells type-1) [−log(p-value) = 3.33], and ‘CD40 signaling’ [−log(p-value) = 3.23] (Fig. 3A, 
Supplementary Table S2). ERK-related family proteins play well-established roles as intracellular messengers dur-
ing chronic inflammatory diseases, controlling multiple cellular processes that regulate cell differentiation, pro-
liferation, and apoptosis, by binding the TFs AP-1 (activator protein-1) and nuclear factor-kappa B (NF-κB)36–39. 
TREM-1 signaling is dramatically induced in psoriasis and contributes to acute inflammation via recruitment 
of multiple cytokines40. CD40 signaling activates section of proinflammatory cytokines (TNF-a, IL-12), which 
promote T-cell survival and differentiation into the Th1 type in various autoimmune diseases41,42.
IPA Disease Bio-Function analyses pointed out the most significantly enriched diseases and biological func-
tions at 2 weeks were associated with ‘skin cancer’ [194 target genes from DEGs; −log(p-value) = 14.88] and 
‘formation of skin’ [37 target genes, −log(p-value) = 14] (Fig. 3B, Supplementary Table S3). By contrast, at 10 
weeks the most enriched diseases and functions were ‘atopic dermatitis’ [22 target genes, −log(p-value) = 7], 
‘hypersensitive reaction’ [34 target genes, −log(p-value) = 9], ‘T-cell lymphoproliferative disorder’ [30 target 
genes, −log(p-value) = 5.7], and ‘allergy’ [33 target genes, −log(p-value) = 8.9] (Supplementary Table S3). Taken 
together, these analyses suggest that the loss of Socs3 affects formation and morphology of skin and initiates skin 
inflammation by activating various hypersensitivity reactions, followed by systematic autoimmune proinflam-
matory responses11,43.
Expression of AP-1 family members is significantly altered in Socs3 cKO keratinocytes. Genes 
related to critical cellular functions are often under tight transcriptional control. To elucidate the core transcrip-
tional machinery responsible for differential gene expression, we sought to identify potential TFs that were signif-
icantly enriched based on their fold change and overlap p-values (Supplementary Table S4) in 2- and 10-week-old 
Socs3 KO mice. For the up-regulated DEGs, IPA revealed significant enrichment of targets involved in regulation 
of AP-1 signaling (Fos, FosB, Atf3, and FosL1) (Fig. 4A). AP-1 proteins play major roles in keratinocyte growth, 
proliferation, and apoptosis44–49. Moreover, various keratin family genes, along with pro-filaggrin and other 
Figure 3. Enriched pathway and bio-function analysis of Socs3 cKO. (A) Top 10 enriched canonical pathways, 
selected based on −log(p-value). (B) Functional annotation of the top enriched disease and bio-function 
analysis at 2 and 10 weeks. Bar size indicates the level of significance for each pathway [i.e., −log(p-value)].
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epidermal growth factor–associated genes that are crucial for skin homeostasis, are also controlled by AP-1 fam-
ily members44,49–54. Thus, perturbation of AP-1–mediated transcription leads to disrupted skin homeostasis and 
altered expression of cytokines and chemokines, eventually leading to disease phenotypes including hyperplasia, 
hyperkeratosis, psoriasis, and cancer44,55,56. Notably in this regard, we also identified PPARG, EHF (ETS subfamily 
homologue), and S100A9, an important regulator of genes involved in keratinocyte differentiation, lipid metabo-
lism, and skin barrier homeostasis, among the top regulators in 2-week-old Socs3 cKO mice, in accordance with 
the enriched canonical pathways shown in Fig. 3A.
To further elucidate the network of shared AP-1 TFs and their target molecules, we constructed an AP-1 TF 
regulatory network using the DEGs from 10-week-old mice. Figure 4B highlights some of the nearest neighbors 
of AP-1 TFs and the top associated biological functions and diseases. This analysis revealed that these TFs have 
important functions in dermatological diseases such as psoriasis (p-value = 4.29 × 10−10) and cellular processes 
associated with differentiation (p-value = 3.02 × 10−12), proliferation (p-value = 2.36 × 10−13), and lesion mor-
phology (p-value = 1.14 × 10−10) (Fig. 4B). Collectively, our TF analyses demonstrate the importance of AP-1–
related TFs in Socs3 cKO, and identified several AP-1 TFs (fos, fosl2, Jun) worthy of validation in human cell 
culture.
SOCS3 depletion causes time-dependent up-regulation of mRNAs encoding AP-1 elements in 
cultured human keratinocytes. Our RNA-Seq analyses suggested the involvement of Socs3 in regulation 
of AP-1 TF genes. To extend these findings, we asked whether this regulatory connection could also be observed 
in SOCS3-knockdown human keratinocytes. To this end, we used two different siRNAs specifically targeting 
SOCS3 mRNA (SOCS3 si#1 and SOCS3 si#2) to decrease expression of SOCS3 in HaCaT cells, and then used 
quantitative real-time PCR to measure the mRNA levels of AP-1–related TFs at various time points after trans-
fection. Transfection with SOCS3 si#1 decreased SOCS3 mRNA expression to 45.6%, 32.4%, 41.8%, and 59.5% of 
the control level at 12, 24, 48, and 72 h post-transfection, respectively (Fig. 5A). The SOCS3 protein level was also 
reduced at later time points (67.9% and 49.0% of the control level at 48 and 72 h post-transfection, respectively, 
but no significant reduction at 12 or 24 h) (Supplementary Figure S1).
We then investigated the effect of SOCS3 depletion on mRNA levels of genes encoding AP-1 factors such 
as c-JUN (JUN), c-FOS (FOS), and FRA2 (FOSL2). All of these genes were affected by Socs3 depletion in dif-
ferent manners and to varying extents, suggesting that Socs3 indeed regulates AP-1 genes (Fig. 5). The mRNA 
levels of c-JUN and FRA2 increased in a time-dependent manner following SOCS3 depletion (Fig. 5B,C). The 
FRA2 mRNA level in SOCS3 siRNA–transfected cells was similar to that in control cells 12 h post-transfection, 
but then started to rise over time (28.5%, 58.8%, and 60.2% higher than the control level at 24, 48, and 72 h 
post-transfection, respectively) (Fig. 5C). The JUN mRNA level exhibited a remarkable time-dependent increase 
under SOCS3 depletion, reaching levels 50.2% and 105.3% higher than those in control cells at 48 and 72 h 
post-transfection, respectively, although this increase was not apparent at 24 h post-transfection (Fig. 5B). By 
contrast, the FOS mRNA level was slightly elevated at 42 and 72 h post-transfection, but the effect was not sig-
nificant (Fig. 5D). Taken together, these observations suggest a difference in the regulation of AP-1 subunits 
Figure 4. Transcription regulator network revealed that several regulators of AP-1 are altered in Socs3 cKO. (A) 
Upstream analysis was performed using IPA software to identify highly regulated transcription factors at 2 and 
10 weeks in Socs3 cKO. Activator protein-1 (AP-1)-related transcription factors were differentially regulated at 
both time points. (B) Predicted mechanistic network of AP-1 regulation; numbers represent log2(fold change) 
of AP-1–related genes. Different structures of nodes represent different functional classes of gene products. 
Red indicates DEGs selected for validation. The nature of the relationship between nodes (direct or indirect) is 
indicated by a solid or dotted line, respectively.
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genes by SOCS3, possibly mediated by SOCS3-dependent regulatory pathways as reported previously in kerat-
inocytes44,57,58. Similar mRNA patterns for JUN, FRA2, and FOS were observed in cells transfected with SOCS3 
si#2 (Supplementary Figure S2).
To confirm that the increase in AP-1 gene expression was reflected by a corresponding increase in protein 
expression, we measured the c-JUN protein level in SOCS3-knockdown (using SOCS3 si#1) HaCaT cells at 72 h 
post-transfection (Supplementary Figure S3). SOCS3-knockdown HaCaT cells exhibited significant increases 
in both phosphorylated and un-phosphorylated c-JUN protein, further supporting our RNA-Seq and qRT-PCR 
observations. Given that SOCS3 si#1 decreased the SOCS3 protein level only after 24 h, the JUN and FRA2 mRNA 
levels seemed to most closely reflect the change in SOCS3 protein level among the AP-1 genes we tested, suggest-
ing a link between SOCS3 and AP-1–related TFs such as c-JUN.
Discussion
To obtain a basic understanding of the role of Socs3 in epidermal homeostasis, we generated and analyzed tran-
scriptome profiles from mice in which Socs3 was conditionally knocked out in keratinocytes. RNA-Seq data from 
Figure 5. Differential expression of AP-1 genes upon SOCS3 depletion. (A–D) HaCaT cells were transfected 
with SOCS3 or control siRNA. At 0 (pre-transfection), 12, 24, 48, and 72 h post-transfection, mRNA levels of 
SOCS3 (A), JUN (B), FRA2 (C), and FOS (D) were quantitated by qRT-PCR. mRNA levels were normalized 
against β-actin mRNA. (n = 5, p < 0.05).
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Socs3 cKO mice at 2 and 10 weeks of age were analyzed to identify the most significantly dysregulated genes 
and their associated molecular pathways. The results revealed that a series of molecular perturbations in the 
epidermis began at 2 weeks that ultimately led to a skin disease–like phenotype13, indicating that Socs3 plays an 
important role in skin barrier homeostasis. Loss of Socs3 in keratinocytes resulted in down-regulation of several 
genes related to epidermal development and barrier function at a very early age (2 weeks), followed by perturba-
tion in genes associated with activation of multiple proinflammatory cytokines and stress-related pathways at 10 
weeks (Figs 1 and 2). AP-1 TFs, in particular c-Jun, were highly up-regulated in later life in cKO mice, and this 
up-regulation was verified in SOCS3-knockdown HaCaT human primary keratinocytes (Figs 4 and 5).
In the epidermis, keratinocytes perform multiple complex tasks, including coordinated proliferation, differ-
entiation, and orchestrated immune responses to intercommunicate with other cell types, all of which contribute 
to maintenance of skin homeostasis59,60. Our RNA-Seq analyses demonstrated that the expression levels of var-
ious genes involved in these highly specialized molecular events were significantly affected in Socs3 cKO mice 
(Figs 1 and 2) at an early stage of development (2 weeks). At that time point, most keratin genes were drastically 
down-regulated, and the expression of genes involved in maintenance of skin barrier function (e.g., SPs, Sprr2i, 
Serpinb7) was altered (Fig. 2). The impact of impaired epidermal organization is likely to be exacerbated by 
hyper-activation of immune and stress responses (Fig. 2; S100A8, S100A9, beta defensin, IL-6), reflecting invasion 
by microbes or irritants61–65, and up-regulation of lipid metabolism, reflecting the high demand for lipid synthesis 
to compensate for reduced barrier hydrophobicity66 (Fig. 2). Thus, the epidermis had reached a pre-disease state 
in young Socs3 KO mice.
Numerous studies using animal models have demonstrated the critical importance of Socs3 in restraining 
inflammatory skin diseases13,14,67,68. Under normal conditions, Socs3 works as an anti-inflammatory checkpoint 
that controls the regulation of various cytokine-triggered immune responses by inhibiting IL-6–induced activa-
tion of the STAT3 signaling pathway4,13,14,67,68. However, hyper-activation of STAT3 in keratinocytes under SOCS3 
depletion induces higher levels of proinflammatory cytokines IL-19, IL-20, and IL-24, resulting in severe inflam-
mation, hyperplasia, and keratinocyte hyper-proliferation13. Moreover, double knockout of Socs3 and Il-6, but not 
Il-4 and Il-13, rescues skin lesions induced by Socs3 KO13. In addition, Socs3 negatively regulates uncontrolled 
interferon-γ (IFN-γ) signaling, which is responsible for severe inflammation in various cell types69–74. Taken 
together, these findings suggest that Socs3 prevents disruption of homeostasis, which would impair skin barrier 
function. Thus, the ‘snapshots’ of disease progression extracted from our findings suggest a sequence of latent, but 
highly dynamic, molecular shifts in Socs3 cKO keratinocytes, starting from an early stage and ultimately leading 
to disease phenotype at later time points. This suggests in turn that Socs3 deficiency triggers hyper-activation of 
immune responses, leading to impaired skin barrier homeostasis at 15 weeks13. Although our findings elucidate 
some of the key phenomena that occur during the early stage of skin disease progression, further study will be 
required to elucidate the detailed mechanism.
AP-1 TFs play important roles in differentiation and proliferation of epidermal keratinocytes44,45,47,53,54,75,76. 
Consistent with this, disruption of AP-1 function affects the onset of various diseases phenotypes, including 
psoriasis development and atopic dermatitis. The link between Socs3 and AP-1 transcriptional activity has 
been reported previously77. Socs3 suppresses AP-1 activity by inhibiting c-JUN phosphorylation in neuroblas-
toma cells77. On the other hand, Socs3 depletion increases AP-1–related transcript levels in oligodendrocytes78. 
Moreover, elevated expression of c-Jun in the suprabasal epidermis results in extensive hyperplasia and hyper-
keratosis, which are hallmarks of psoriatic skin79–81. Our transcriptome analysis suggests that Socs3-dependent 
AP-1 transcriptional regulation might play a significant role in maintaining epidermal homeostasis, although the 
detailed regulatory mechanisms remain to be elucidated. It is possible that the induction of AP-1–related genes is 
due to early activation of p38 MAPK signaling (Fig. 3A), which is involved in the regulation of both gene groups 
in various contexts82–86.
Taken together, our results reveal novel regulatory dynamics of Socs3, which plays a pivotal role in regulating 
important genes involved in skin homeostasis. Our observations provide insights into the mechanisms under-
lying maintenance of skin homeostasis, in which Socs3 (in cooperation with other genes) orchestrates multiple 
essential events such as keratinocyte proliferation, differentiation, and immune or stress responses. In addition, 
experimental validation of our computation-driven hypothesis in human keratinocytes confirmed the role of 
Socs3 in the regulation of AP-1 TF genes. Future studies, including detailed time-series analysis and modeling of 
molecular interactions, will help us to understand the role of Socs3 dynamics in the maintenance of skin homeo-
stasis and skin disease progression.
Materials and Methods
Animal model. The keratin 5–specific Socs3 cKO mouse was generated in the C57BL/6 background as 
described previously13. All mice used in this study were maintained in specific pathogen–free (SPF) conditions. 
Prior approval for animal experiments was obtained from the Animal Research Ethics Committee of RIKEN 
Yokohama, Japan. All mice were maintained and studied in accordance with the guidelines of the RIKEN Animal 
Research Committee.
RNA-Seq sample preparation. Total RNA was isolated using TRIzol (Thermo Fisher Scientific, Waltham, 
MA, USA) from ear samples of wild-type (n = 6 at 2 weeks, and n = 4 at 10 weeks) and Socs3-deficient mice (n = 4 
at 2 weeks, and n = 4 at 10 weeks) at 2 or 10 weeks of age. cDNA libraries were synthesized using the TruSeq RNA 
Library Preparation Kit v2 (Illumina, San Diego, CA, USA). Sequencing data were generated on a HiSeq. 1000 
system (Illumina) as single-ended 50-base reads. EdgeR package20 in the R statistical environment was used to 
analyze DEGs. The Orange software75 was used to draw Venn diagrams to depict DEGs at both time points.
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Data availability statement. All data related to this study have been deposited in the public repository 
Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) with accession number GSE94743.
Cell culture and antibodies. The human keratinocyte–derived HaCaT cell line was maintained at 37 °C 
with 5.0% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) with high glucose and high pyruvate (Gibco) 
supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin (Gibco), and 100 U/ml streptomycin 
(Gibco). Rabbit anti-SOCS antibody (#2923, Cell Signaling Technology), rabbit c-Jun (60A8) antibody (#9165, 
Cell Signaling Technology), rabbit Phospho-c-Jun (Ser63) (54B3) antibody (#2361, Cell Signaling Technology), 
and mouse anti-β-actin antibody [Anti-BETA-Actin (C4): sc-47778; Santa Cruz Biotechnology] were used for 
immunoblot analysis. Horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG and donkey anti-rabbit 
IgG were purchased from GE Healthcare.
Socs3 knockdown in HaCaT cells. Two different siRNAs targeting SOCS3 mRNA were used 
to knock down SOCS3 in HaCaT cells. SOCS3 si#1 (5′-CGCUCAGCGUCAAGACCCAdTdT-3′ and 
5′-UGGGUCUUGACGCUGAGCGdTdT-3′) and a control siRNA (5′-CCUACGCCACCAAUUUCGUdTdT-3′ 
and 5′-ACGAAAUUGGUGGCGUAGGdTdT-3′) were synthesized by Eurofins Genomics. The second siRNA 
(SOCS3 si#2) against target sequence ‘CACCUGGACUCCUAUGAGA’ was purchased from ON-TARGETplus 
Human SOCS3 (9021) siRNA (GE Dharmacon™). Both siRNAs were transfected into cells using INTERFERin 
(Polyplus-transfection, New York, NY, USA). SOCS3 knockdown was confirmed by measurement of SOCS3 
mRNA (for both Socs3 si#1 and si#2) and SOCS3 protein levels (for Socs3 si#1 only) at 12, 24, 48, and 72 h 
post-transfection. SOCS3 si#1, n = 5; SOCS3 si#2, n = 3.
Quantitative real-time PCR (qRT-PCR). Total RNA was prepared from cells on a Maxwell 16 Automated 
Purification System (Promega) using the Maxwell LEV simplyRNA Tissue Kit (Promega), and then subjected 
to reverse transcription to synthesize complementary DNA (cDNA) using ReverTra Ace qPCR RT Master Mix 
(TOYOBO). Specific primers for the SOCS3, β-actin, and AP-1 genes were synthesized by Eurofins Genomics 
(Supplementary Figure S4). cDNA was amplified on a LightCycler 480 II instrument (Roche) with LightCycler 
480 SYBR Green I Master (Roche) under the following reaction conditions: 45 cycles of 95 °C for 10 sec, 60 °C for 
10 sec, and 72 °C for 10 sec. Relative mRNA levels were determined based on the ∆∆Ct method, and normalized 
against β-actin mRNA
Enriched functional pathway and transcriptional regulator analysis. Canonical biological path-
ways were identified using the IPA software (www.qiagen.com/ingenuity). Fisher’s exact test method (fold 
change ≥ 2) was used to determine the probability of each disease and biological pathway based on genes differ-
entially expressed at 2 and 10 weeks. For functional network and upstream transcriptional analysis, DEGs (fold 
change ≥ 2) were clustered into networks of known connections, biological functions, and associated diseases 
(p-values ≤ 0.05), based on a knowledge database and published references. The analysis identified how many 
known targets of the TFs were present in the Socs3 cKO dataset, and also the degree of change with respect to the 
WT. Overlap p-value was computed based on significant overlap between DEGs in the dataset and the known 
targets of transcriptional regulators.
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